Your session is about to expire
← Back to Search
Radiation
Radiation Therapy for Neuroblastoma
N/A
Recruiting
Led By David Kozono, MD, PhD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
Study Summary
This trial aims to understand how radiation treats cancer while avoiding side effects, by collecting data & biospecimens before, during & after radiation & annotating them w/clinical, biological & other features.
Who is the study for?
This trial is for children and young adults with specific types of brain tumors or high-risk neuroblastoma. Participants must meet certain age, health, and diagnostic criteria, have stable vital functions, and not be pregnant or breastfeeding. They should also be enrolled in one of the specified clinical trials related to their condition.Check my eligibility
What is being tested?
The MCT aims to collect detailed biological data from patients undergoing radiation therapy for tumor treatment. It involves external beam radiotherapy and a radioactive drug called 131I-MIBG to understand how these treatments work against tumors while assessing potential side effects.See study design
What are the potential side effects?
Potential side effects may include damage to healthy tissues due to radiation exposure, thyroid issues from radioactive iodine (131I-MIBG), fatigue, nausea, blood count changes leading to increased infection risk or bleeding problems.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Event-free survival by DNA damage response
Event-free survival by tumor DNA alterations
Event-free survival by tumor heterogeneity
Secondary outcome measures
Proportion of patients with serious adverse events by DNA damage response
Trial Design
2Treatment groups
Experimental Treatment
Group I: NeuroblastomaExperimental Treatment1 Intervention
Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B
Group II: Diffuse Midline GliomaExperimental Treatment1 Intervention
Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
External beam radiotherapy
2004
Completed Phase 2
~130
Find a Location
Who is running the clinical trial?
Brigham and Women's HospitalLead Sponsor
1,616 Previous Clinical Trials
11,470,903 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,669 Previous Clinical Trials
40,926,354 Total Patients Enrolled
205 Trials studying Neuroblastoma
53,637 Patients Enrolled for Neuroblastoma
Dana-Farber Cancer InstituteOTHER
1,079 Previous Clinical Trials
340,933 Total Patients Enrolled
10 Trials studying Neuroblastoma
3,933 Patients Enrolled for Neuroblastoma
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there opportunities for enrolment in this investigation?
"According to clinicaltrials.gov, this trial is not open for enrollment as of August 17th 2023, and was originally posted on the 21st of August in the same year. However, there are 159 other trials currently recruiting patients at present."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger